Neuromyélite optique de devic spectrum disorder

Rare : 1/100 000
Etemadifar 2015

Pronostic sévère
Wingerchuk, 1999, Neurology

Névrite optique



Atteinte du tronc cérébrale



Myélite transverse étendue



AQP4



Atteinte encéphalique



Traitement de fond

- Azathioprine (Mandler, 1998)
- PLEX (Weinschenker, 1999)
- Immunosuppresseurs (Papeix, 2003)
- Rituximab (Cree, 2005)
- MFM (Jacob, 2009)
- Tocilizumab (Araki, 2014)

Comparaison du taux annualisé de poussées pré et sous traitement chez les patients NMO

Table 2. Treatment-Associated Annualized Relapse Rates (ARRs) and Hazard Risks Relative to Rituximab

Medication	Pretreatment ARR	Posttreatment ARR	Change From Pretreatment to Posttreatment, %	Hazard Risk Relative to Rituximab (95% CI)	*P* Value
Azathioprine	2.26	0.63	72.1	2.12 (1.12- 4.01)	.02
Mycophenolate mofetil					
Total	2.61	0.33	87.4	1.48 (0.75-2.93)	.26
Optimal dosing	2.55	0.25	90.2		
Rituximab					
Total	2.89	0.33	88.6	1 [Reference]	
Optimal dosing	3.25	0.20	93.9		
Switch treatments	1.03	0.14	86.4		.054

JAMA Neurol. 2014;71(3):324-330.

Perspectives thérapeutiques

Anti Bcell
- ✓ Anti CD20
- ✓ **Anti CD19 (inebilizumab)**

Anti IL6
- ✓ Tocilizumab
- ✓ **satralizumab**

Aquaporumab

Eculizumab

Sivelestat



Ratelade, verkman, 2012 Int J Biochem Cell Biol.

RéSumé des principaux résultats

	PREVENT Eculizumab Anti- C5	N-MOmentum Inebilizumab Anti-CD19	Sakura- Sky Sartralizumab Anti –IL6R	Sakura-star Sartralizumab Anti –IL6R
Sujets	AQP4+ 143	AQP4 + et - (212+18)=230	AQP4 + et - (55+28)=83	AQP4 + et - (64+31)=95
Bras placebo	Déjà sous IS	PBo seul	Déjà sous IS	PBo seul

Ce que nous disent les résultats de ces 4 essais

- Les trois traitements sont très efficaces sur la prévention des poussées
- Meilleure efficacité chez AQP4 +
- Analyses de sous groupes Eculizumab et inebilizumab
  - Efficacité sur la sévérité des poussées et une meilleure récupération

Traitement des poussées

O'Riordan *et al.* 1996. JNNP.

Mandler *et al*, 1998, Ann Neurol..

- **Corticoïdes : 5 à 10 g en IVL pas de relais PO**
- **Plasmaphérèse : 7 EP**
  - Possibilité de mixer Solumédrol et EP
  - Ac monoclonal 24 h après EP
  - Facteur de recupération complète :
    - Utilisation en 1ère ligne
    - Délai de traitement court
    - AQP4 +
    - Atteinte mono focale



ARTICLE OPEN ACCESS CLASS OF EVIDENCE

Apheresis therapies for NMOSD attacks

A retrospective study of 207 therapeutic interventions

Ingo Kleiter, MD, Anna Gahlen, MD, Nadja Borisow, MD, Katrin Fischer, MD, Klaus-Dieter Wernecke, PhD, Kerstin Hellwig, MD, Florence Pache, MD, Klemens Ruprecht, MD, Joachim Havla, MD, Tania Kümpfel, MD, Orhan Aktas, MD, Hans-Peter Hartung, MD, Marius Ringelstein, MD, Christian Geis, MD, Christoph Kleinschnitz, MD, Achim Berthele, MD, Bernhard Hemmer, MD, Klemens Angstwurm, MD, Jan-Patrick Stellmann, MD, Simon Schuster, MD, Martin Stangel, MD, Florian Lauda, MD, Hayrettin Tumani, MD, Christoph Mayer, MD, Markus Krumbholz, MD, Lena Zeltner, MD, Ulf Ziemann, MD, Ralf Linker, MD, Matthias Schwab, MD, Martin Marziniak, MD, Florian Then Bergh, MD, Ulrich Hofstadt-van Oy, MD, Oliver Neuhaus, MD, Uwe K. Zettl, MD, Jürgen Faiss, MD, Brigitte Wildemann, MD, Friedemann Paul, MD, Sven Jarius, MD, and Corinna Trebst, MD, on behalf of NEMOS (Neuromyelitis Optica Study Group)

Correspondence
Dr. Kleiter
ingo.kleiter@rub.de

Neurol Neuroimmunol Neuroinflamm 2018;5:e504. doi:10.1212/NXL.0000000000000504

Abstract

Objective
To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).

Methods
This retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with aquaporin-4 (AQP4-ab)-antibody–seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March 2013. Besides descriptive data analysis of patient and attack characteristics, generalized estimation equation (GEE) analyses were applied to compare the effectiveness of the 2 apheresis techniques. A GEE model was generated to assess predictors of outcome.

Results
Two hundred and seven attacks in 105 patients (87% AQP4-ab-antibody seropositive) were treated with at least 1 apheresis therapy. Neither PE nor IA was proven superior in the therapy of NMOSD attacks. CR was only achieved with early apheresis therapy. Strong predictors for CR were the use of apheresis therapy as first-line therapy (OR 12.27, 95% CI: 1.04–144.91, $p = 0.047$), time from onset of attack to start of therapy in days (OR 0.94, 95% CI: 0.89–0.99, $p = 0.014$), the presence of AQP4-ab-antibodies (OR 33.34, 95% CI: 1.76–631.17, $p = 0.019$), and monofocal attack manifestation (OR 4.71, 95% CI: 1.03–21.62, $p = 0.046$).

Conclusions
Our findings suggest early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients. No superiority was shown for one of the 2 apheresis techniques.

Classification of evidence
This study provides Class IV evidence that for patients with NMOSD, neither PE nor IA is superior in the treatment of attacks.

RELATED ARTICLE

Editorial
Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders
Page e510

MORE ONLINE

→ **Class of Evidence**
Criteria for rating therapeutic and diagnostic studies
NPub.org/coe

Les interrogations qui persistent

- les effets à long terme
  - efficacité
  - Tolérance
- Durée du traitement
- Identification de facteurs prédictifs de poussée pour escalade?
  - NLF and GFAP
  - Dosage des CD19
- Doit on le proposer aux AQP4 négatifs ? Anti MOG ?

Anti MOG

Reindl, Nature Reviews Neurology 2019



Etude comparative des NMOSD AQP4+ et anti MOG +

JAMA Neurol. 2014;71(3):276-283. doi:10.1001/jamaneurol.2013.5857

Table 1. Comparison of Clinical Features in Patients With MOG-Ab–Positive and AQP4-Ab–Positive NMO/NMOSD

Feature	MOG-Ab Positive (n = 9)	AQP4-Ab Positive (n = 20)	*P* Value
Follow-up, median (range), mo	18.00 (2.2-38.5)	20.47 (5.0-36.6)	NS
Female, %	44	90	.02
White, %	78	60	NS
Age at onset, mean (SD), y	32.29 (17.1)	44.86 (14.8)	.05
Coexisting autoimmunity, No. (%)	1 (11)	9 (45)	NS
Onset episode, No. (%)			
ON only	0 (0)	6 (30)	NS
TM only	3 (33)	12 (60)	NS
ON+TM	4 (44)	0 (0)	.005
Brain/brainstem+TM	2 (22)	0 (0)	NS
Brain only	0 (0)	2 (10)	NS
Nadir EDSS score, median (range)	6.0 (4-8.5)	5.5 (1-8.5)	NS
EDSS score at best recovery, median (range)	0 (0-2.5)	4.0 (0-8)	.01
Patients with TM at onset left motor disabled, No. (%)	0 (0)	7 (58)	.007
Patients with ON at onset left visually disabled, No. (%)	0 (0)	2 (33)	NS
Subsequent relapse, No. (%)	0 (0)	8 (40)	.03

Abbreviations: Ab, antibody; AQP4, aquaporin-4; EDSS, Expanded Disability Status Scale; MOG, myelin-oligodendrocyte glycoprotein; NMO, neuromyelitis optica; NS, not significant; ON, optic neuritis; SD, spectrum disorder; TM, transverse myelitis.

Etude comparative des NMOSD AQP4+ et anti MOG +

JAMA Neurol. 2014;71(3):276-283. doi:10.1001/jamaneurol.2013.5857



Figure Legend:

Expanded Disability Status Scale (EDSS) Scores at Nadir and Recovery of the Onset EpisodePatients with aquarorin-4 antibody (AQP4-Ab)–positive neuromyelitis optica/neuromyelitis optica spectrum disorder often showed poor recovery from the acute episode (left), with little change in EDSS scores, whereas recovery in myelin-oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients was often dramatic (right). The median change in EDSS scores between episode nadir and recovery was significantly higher in MOG-Ab–positive patients compared with AQP4-Ab–positive patients (6 vs 2; P<.001).

Histologie

	MOG	AQP4
Démyélinisation	**primaire** bien délimitée Macrophages avec débris de myéline	**secondaire**
Astrocytes	Préservation relative	Perte +++
Infiltrat inflammatoire	lymphocytes T , qq B Péri-vasculaires	PNN et PNEo
Dépôts de complément Avec complexe terminal	oui	Oui + dépôt d'IgG
Pré-OGD	Préservation des pré-OGD immature (n'exprime pas la MOG)	

RESEARCH Open Access

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Alvaro Cobo-Calvo[1,2,18], María Sepúlveda[3], Fabien Rollot[4,5], Thais Armangué[3,6], Anne Ruiz[2], Elisabeth Maillart[7], Caroline Papeix[7], Bertrand Audoin[8], Helene Zephir[9], Damien Biotti[10], Jonathan Ciron[10], Francoise Durand-Dubief[1], Nicolas Collongues[11], Xavier Ayrignac[12], Pierre Labauge[12], Eric Thouvenot[13], Bertrand Bourre[14], Alexis Montcuquet[15], Mikael Cohen[16], Romain Deschamps[17], Nuria Solà-Valls[3], Sara Llufriu[3], Jerome De Seze[11], Yolanda Blanco[3], Sandra Vukusic[1,18], Albert Saiz[3] and Romain Marignier[1,2,18*]

JNeuroinflammation, 2019

- 165 patients adultes MOG +
  - 59 non traités et 66 traités

Table 3 Evaluation of pre-treatment and on-treatment annualised relapse ratio and EDSS according to treatment group

Treatment group		Treated ≥ 6 months at any time, *n* (%)	Eligible for analysis, *n* (%)	FU before treatment (years), median (range)	FU under treatment (years), median (range)	ARR pre/ on-treatment, mean (SD)	Freedom of relapse on-treatment *n* (%)	*p* value ARR pre/ on-treatment	EDSS pre/ end of treatment, mean (SD)	Freedom of EDSS progression, *n* (%)	*p* value EDSS pre/end-treatment
Type I IS	AZT	19/66 (28.8)	11/19 (57.9)	2.4 (0.6–7.6)	2.1 (0.5–12.6)	1.05 (1.20)/ 0.43 (0.79)	6 (54.5)	0.041	1.86 (1.30)/ 1.68 (1.19)	11 (100)	0.157
	MMF	12/66 (18.2)	11/12 (91.7)	1.7 (0.5–46.4)	1.7 (0.5–6.8)	1.20 (1.11)/ 0.23 (0.60)	8 (72.7)	0.033	2.72 (1.69)/ 2.64 (1.76)	11 (100)	0.317
	RTX	30/66 (45.5)	26/30 (86.7)	3.3 (0.5–18.33)	1.7 (0.5–4.9)	1.08 (0.98)/ 0.43 (0.89)	19 (73.1)	0.012	3.11 (1.83)/ 2.58 (1.90)	23 (88.5)	0.096
Type II IS		6/66 (9.1)	5/6 (83.3)	5.2 (2.9–10.3)	2.0 (0.6–3.7)	0.64 (0.45)/ 0.65 (0.69)	2 (40)	0.893	3.8 (1.52)/ 4.0 (1.45)	1 (20.0)	0.317
Type III IS		8/66 (12.1)	3/8 (37.5)	–	–	–	–	–	–	–	–
[a]MS-DMD		10/66 (6.6)	9/10 (90)	1.95 (0.5–20.1)	3.7 (1.0–14.7)	1.13 (1.38)/ 0.49 (0.41)	2 (22.2)	0.374	2.5 (0.90)/ 3.17 (2.15)	7 (77.7)	0.188

*Patients treated with type III IS (corticosteroids, $n = 2$ and intravenous immunoglobulins, $n = 1$) were not eligible for analysis due to treated number ≤ 5

[a]Among the 9 patients with MS-DMD eligible for the analysis, 2 patients were treated with natalizumab, 1 with glatiramer acetate and 6 with interferon

FU follow-up, *ARR* annualised relapse ratio, *SD* standard deviation, *EDSS* Expanded Disability Status Scale, *IS* immunosuppressants, *MS-DMD* multiple sclerosis disease-modifying drugs, *AZT* azathioprine, *MMF* mycophenolate mophetil, *RTX* rituximab

Ac anti-CD20 chez les MOG ?

- Etude rétrospective de 121 patients (13 pays): 30 enfants / **91 adultes**
  - 20 traités dès P1: 30% qui rechutent (médiane 2 mois)
  - 101 traités à partir de P2 ou plus tard:

Rechute sous anti-CD20:
CD19 < 1% ds 79%

	n	Diminution du taux de poussée	Survie sans poussée à 2 ans
n	101	37% 95%CI:19-52%, p< 0.001	
En 1ere ligne	47	63% 95%CI:35-79%, p= 0.001	55%
En 2° ou 3° ligne (après AZA/MMF)	54	26% 95%CI:2-44%, p = 0,038	18%

Efficacité des IVIG chez les NMO anti –MOG

IgIV induction à 2g/KG puis 1 g/kg

		Nombre de patients	TAP avant	TAP après
Hachachen et *al*. 2018	MOG	16	2,6	0,51
Ramanathan et *al.* 2017	MOG	7	2	0
Jarius et *al.* 2016	MOG	1		0
Viwanathan et *al.* 2015	AQP4	6	0,75	1,5
Karthikeayan *P734 Ectrims 2019*	MOG	3	2,02	0,13

Cout ? Durée?

Conclusion